ArticleFrontiers in immunology2026
Prognostic inflammatory-immune score-based risk stratification optimizes adjuvant therapy for non-gastric gastrointestinal stromal tumors: a multicenter study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Conventional modified National Institutes of Health (mNIH) and Armed Forces Institute of Pathology (AFIP) systems exhibit "anatomical bias" due to their development from predominantly gastric cohorts, resulting in suboptimal prognostic performance in non-gastric gastrointestinal stromal tumors (GISTs). This study aimed to develop an integrated model to refine risk stratification and guide adjuvant imatinib duration in non-gastric GIST. Methods: A multicenter retrospective cohort of 471 patients with non-gastric GIST was analyzed. Hematological variables were screened using the Boruta algorithm to construct a Prognostic Inflammatory-Immune Score (PIIS), which was integrated with clinicopathological factors to develop a nomogram. Feature contributions were interpreted using Shapley Additive Explanations (SHAP). Risk re-stratification was conducted to evaluate benefits of different adjuvant imatinib durations. Results: The PIIS comprised the platelet-to-albumin ratio (PAR), platelet-to-lymphocyte ratio (PLR), derived neutrophil-to-lymphocyte ratio (dNLR), and lactate dehydrogenase-to-albumin ratio (LAR). Multivariable analysis identified sex, tumor size, mitotic index, Ki-67 index, and PIIS as independent predictors of recurrence-free survival (RFS). The integrated model demonstrated superior discrimination, with C-indices of 0.839 in the training cohort and 0.795 in the external validation cohort, outperforming mNIH and AFIP. The model revealed substantial heterogeneity within conventional risk categories and stratified mNIH high-risk and AFIP intermediate- and high-risk patients into low-, medium-, and high-risk groups. In model-defined medium- and high-risk subgroups, adjuvant therapy beyond 3 years was associated with improved RFS, whereas no clear additional benefit was observed in the low-risk subgroup. Conclusions: This multicenter-validated nomogram may improve recurrence risk prediction in non-gastric GIST and may provide a useful reference for risk-adapted adjuvant therapy planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.